Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer

Abstract

Predicting the risk of metastasis before starting prostate cancer (PCa) treatment can minimize the overtreatment of indolent cases and help choosing appropriate treatment. The levels of circulating microRNAs (miRNAs) from body fluids can be used as noninvasive prognostic biomarkers. In this study, urinary exosomal miRNA expression profiles of 149 PCas were determined and the miRNAs associated with metastasis were identified: miR-21, miR-16, miR-142-3p, miR-451, and miR-636. When evaluating clinical factors together, miR-21, miR-451, miR-636, and preoperative prostate-specific antigen (PSA) level remained significant in the multivariate analysis. Based on them, we developed a “Prostate Cancer Metastasis Risk Scoring (PCa-MRS)” model. The PCa-MRS showed superior stratification power (AUC = 0.925) to preoperative PSA or clinical Gleason score. Patients with high scores showed significantly poorer biochemical recurrence-free survival than those with low scores (P = 6.53 × 10−10). Our results showed the potential of urinary exosomal miRNAs as noninvasive markers for predicting metastasis and prognosis in PCa patients.

Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy

“…In addition to their potential as drug carriers, exosomes have unlimited potential as biomarkers for cancer diagnosis and prognosis. Indeed, numerous studies have been attempted to explore the various profiles and functions of exosomes and to facilitate their clinical applications [171][172][173][174][175]. The potential of exosomes isolated from various body fluids such as blood, saliva, and urine as cancer biomarkers is based on the capture of abnormal cell physiology, but can be expressed differently depending on the source and how to accurately capture unique signals is a major challenge.…”

Exosomes Derived from Radioresistant Breast Cancer Cells Promote Therapeutic Resistance in Naïve Recipient Cells

“…Within the context of solid cancers, although solid biopsy is still the gold standard for pathological diagnosis and basis for treatment, the use of serum-based exosomes as biomarkers of cancer has been demonstrated in gliomas [39][40][41], liver cancers [42,43], endometrial cancer [44] and gastrointestinal cancers [45,46]. Exosomes in urine have also been investigated for their possible use in the diagnosis and prognostication of prostate cancer [47,48]. As the production of exosomes and their composition is altered by radiation treatment, exosomes could potentially be used as non-invasive diagnostic markers for radiosensitivity and to monitor the emergence of radioresistance.…”

Small Extracellular Vesicles and Metastasis—Blame the Messenger

“…The nanovesicles protect proteins from proteolytic cleavage and prevent degradation of enclosed nucleic acids [30]. This is why a large number of miRNAs, but also other ncRNAs, in sEVs have been characterized as biomarkers for prognosis and treatment response during tumor progression and metastasis (see Table 2), e.g., mir-21 in sEVs has been associated with lymph node metastasis in PDAC [240], bone metastasis in BC [241], tumor spinal/ventricle metastasis in glioma [242], lymph node metastasis in laryngeal squamous cell carcinoma (LSCC) [243], metastasis in general in ESCC [243], as well as in multi-miR panels with peritoneal metastasis of GC [244], and metastasis in PC [245] or CRC [246]. In addition to RNA, sEV-DNA was also described as a biomarker for the detection of cancer-specific mutations, since sEV-DNA fragments were shown to stochastically represent the entire genome of cancer cells, including mitochondrial DNA [247,248].…”